[
    [
        {
            "time": "2018-08-08",
            "original_text": "FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%",
            "features": {
                "keywords": [
                    "FDA",
                    "Teva",
                    "Generic",
                    "EpiPen",
                    "Stock Up"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "FDA approves first rival generic EpiPen, sending Teva shares up 6%",
            "features": {
                "keywords": [
                    "FDA",
                    "generic",
                    "EpiPen",
                    "Teva",
                    "shares up"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?",
            "features": {
                "keywords": [
                    "Mylan",
                    "North America",
                    "Sales Down",
                    "Q2 2018"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "MYL Stock Down ~3% since Its Q2 2018 Results on August 8",
            "features": {
                "keywords": [
                    "MYL",
                    "Stock Down",
                    "Q2 2018",
                    "Results"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "The Swiss Stock Market Climbed On Trade Deal Hopes",
            "features": {
                "keywords": [
                    "Swiss Stock Market",
                    "Climbed",
                    "Trade Deal Hopes"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "economy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results",
            "features": {
                "keywords": [
                    "Analysts",
                    "Cut",
                    "Target Prices",
                    "MYL",
                    "Q2 2018"
                ],
                "sentiment_score": -0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-08",
            "original_text": "Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail",
            "features": {
                "keywords": [
                    "Gene Therapy",
                    "Deregulation",
                    "Amazon",
                    "SEC",
                    "Musk"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 4,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]